Tybost

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

cobicistat

Available from:

Gilead Sciences Ireland UC

ATC code:

V03AX03

INN (International Name):

cobicistat

Therapeutic group:

Antivirusi za sistemsko uporabo

Therapeutic area:

Okužbe z virusom HIV

Therapeutic indications:

Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Product summary:

Revision: 15

Authorization status:

Pooblaščeni

Authorization date:

2013-09-19

Patient Information leaflet

                                31
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Irska
12.
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/13/872/001 30 filmsko obloženih tablet
EU/1/13/872/002 90 (3 plastenke po 30) filmsko obloženih tablet
13.
ŠTEVILKA SERIJE
Lot
_ _
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Tybost [samo na zunanji ovojnini]
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako. [samo na
zunanji ovojnini]
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC {številka}
SN {številka}
NN {številka}
[samo na zunanji ovojnini]
32
B. NAVODILO ZA UPORABO
33
NAVODILO ZA UPORABO
TYBOST 150 MG FILMSKO OBLOŽENE TABLETE
kobicistat
PRED ZAČETKOM JEMANJA ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
farmacevtom.
-
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Njim bi lahko celo
škodovalo, čeprav imajo znake bolezni, podobne vašim.
-
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom
ali farmacevtom. Posvetujte
se tudi, če opazite katere koli neželene učinke, ki niso navedeni v
tem navodilu. Glejte
poglavje 4.
KAJ VSEBUJE NAVODILO:
1.
Kaj je zdravilo Tybost in za kaj ga uporabljamo
2.
Kaj morate vedeti, preden boste vzeli zdravilo Tybost
3.
Kako jemati zdravilo Tybost
4.
Možni neželeni učinki
5.
Shranjevanje zdravila Tybost
6.
Vsebina pakiranja in dodatne informacije
1.
KAJ JE ZDRAVILO TYBOST IN ZA KAJ GA UPORABLJAMO
Zdravilo Tybost vsebuje učinkovino kobicistat.
Zdravilo
_ _
Tybost se uporablja za zdravljenje okužbe z virusom humane imunske
pomanjkljivosti 1
(HIV-1), virusa, ki povzroča sindrom pridobljene imunske
poma
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
_ _
Tybost 150 mg filmsko obložene tablete
_ _
_ _
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 150 mg kobicistata.
Pomožne snovi z znanim učinkom
Ena tableta vsebuje 59 mikrogramov barvila sončno rumeno FCF (E110).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
Oranžna, okrogla, bikonveksna, filmsko obložena tableta s premerom
10,3 mm, z vtisnjenim znakom
"GSI" na eni strani tablete in brez oznak na drugi strani tablete.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Tybost je indicirano kot farmakokinetični ojačevalec
atazanavirja 300 mg enkrat na dan ali
darunavirja 800 mg enkrat na dan kot del protiretrovirusnega
kombiniranega zdravljenja pri odraslih in
mladostnikih, starih 12 let ali več, okuženih z virusom humane
imunske pomanjkljivosti 1 (HIV-1), ki:
•
tehtajo najmanj 35 kg, ob sočasnem dajanju atazanavirja, ali
•
tehtajo najmanj 40 kg, ob sočasnem dajanju darunavirja.
Glejte poglavja 4.2, 4.4, 5.1 in 5.2.
4.2
ODMERJANJE IN NAČIN UPORABE
Terapijo mora začeti zdravnik, ki že ima izkušnje z zdravljenjem
okužbe z virusom HIV.
_ _
Odmerjanje
Zdravilo Tybost se uporablja v kombinaciji z atazanavirjem ali
darunavirjem, zato glejte tudi povzetek
glavnih značilnosti zdravila za atazanavir ali darunavir.
Zdravilo Tybost se jemlje peroralno enkrat na dan s hrano.
Odmerek zdravila Tybost in zaviralca proteaze, ki se daje sočasno,
atazanavirja ali darunavirja, je
predstavljen v preglednicah 1 in 2.
PREGLEDNICA 1: REŽIM ODMERJANJA PRI ODRASLIH
ODMEREK ZDRAVILA TYBOST
ODMEREK ZAVIRALCA PROTEAZE HIV-1
150 mg enkrat na dan
atazanavir 300 mg enkrat na dan
darunavir 800 mg enkrat na dan
3
PREGLEDNICA 2: REŽIM ODMERJANJA PRI MLADOSTNIKIH, STARIH 12 LET ALI
VEČ, KI TEHTAJO ≥ 35 KG
TELESNA MASA (KG)
ODMEREK ZDRAVILA TYBOST
ODMEREK ZAVIRALCA PROTEAZE HIV-1
≥ 40
150 mg enkrat na dan
atazanavir 300 mg enkrat na dan
darunavir 8
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-02-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-02-2023
Public Assessment Report Public Assessment Report Bulgarian 29-07-2020
Patient Information leaflet Patient Information leaflet Spanish 14-02-2023
Public Assessment Report Public Assessment Report Spanish 29-07-2020
Patient Information leaflet Patient Information leaflet Czech 14-02-2023
Public Assessment Report Public Assessment Report Czech 29-07-2020
Patient Information leaflet Patient Information leaflet Danish 14-02-2023
Public Assessment Report Public Assessment Report Danish 29-07-2020
Patient Information leaflet Patient Information leaflet German 14-02-2023
Public Assessment Report Public Assessment Report German 29-07-2020
Patient Information leaflet Patient Information leaflet Estonian 14-02-2023
Public Assessment Report Public Assessment Report Estonian 29-07-2020
Patient Information leaflet Patient Information leaflet Greek 14-02-2023
Public Assessment Report Public Assessment Report Greek 29-07-2020
Patient Information leaflet Patient Information leaflet English 14-02-2023
Public Assessment Report Public Assessment Report English 29-07-2020
Patient Information leaflet Patient Information leaflet French 14-02-2023
Public Assessment Report Public Assessment Report French 29-07-2020
Patient Information leaflet Patient Information leaflet Italian 14-02-2023
Public Assessment Report Public Assessment Report Italian 29-07-2020
Patient Information leaflet Patient Information leaflet Latvian 14-02-2023
Public Assessment Report Public Assessment Report Latvian 29-07-2020
Patient Information leaflet Patient Information leaflet Lithuanian 14-02-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-02-2023
Public Assessment Report Public Assessment Report Lithuanian 29-07-2020
Patient Information leaflet Patient Information leaflet Hungarian 14-02-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 14-02-2023
Public Assessment Report Public Assessment Report Hungarian 29-07-2020
Patient Information leaflet Patient Information leaflet Maltese 14-02-2023
Public Assessment Report Public Assessment Report Maltese 29-07-2020
Patient Information leaflet Patient Information leaflet Dutch 14-02-2023
Public Assessment Report Public Assessment Report Dutch 29-07-2020
Patient Information leaflet Patient Information leaflet Polish 14-02-2023
Public Assessment Report Public Assessment Report Polish 29-07-2020
Patient Information leaflet Patient Information leaflet Portuguese 14-02-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 14-02-2023
Public Assessment Report Public Assessment Report Portuguese 29-07-2020
Patient Information leaflet Patient Information leaflet Romanian 14-02-2023
Public Assessment Report Public Assessment Report Romanian 29-07-2020
Patient Information leaflet Patient Information leaflet Slovak 14-02-2023
Public Assessment Report Public Assessment Report Slovak 29-07-2020
Patient Information leaflet Patient Information leaflet Finnish 14-02-2023
Public Assessment Report Public Assessment Report Finnish 29-07-2020
Patient Information leaflet Patient Information leaflet Swedish 14-02-2023
Public Assessment Report Public Assessment Report Swedish 29-07-2020
Patient Information leaflet Patient Information leaflet Norwegian 14-02-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 14-02-2023
Patient Information leaflet Patient Information leaflet Icelandic 14-02-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 14-02-2023
Patient Information leaflet Patient Information leaflet Croatian 14-02-2023
Public Assessment Report Public Assessment Report Croatian 29-07-2020

Search alerts related to this product

View documents history